Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy E Lovett-Racke

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Frontiers in Molecular Neuroscience|November 11, 2017
Suppression of Inflammatory Demyelinaton and Axon Degeneration through Inhibiting Kv3 ChannelsPeter Jukkola, Yuanzheng Gu, Amy E Lovett-Racke, et al.
Expert Review of Clinical Immunology|May 19, 2010
Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosisMark T Muir, Amy E Lovett-Racke, Michael K Racke
Frontiers in Neurology|June 2, 2022
Vitamin D as a Risk Factor for Multiple Sclerosis: Immunoregulatory or Neuroprotective?Sara E Gombash, Priscilla W Lee, Elizabeth Sawdai, et al.
Brain, Behavior, and Immunity|December 16, 2014
Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosisPriscilla W Lee, Yuhong Yang, Michael K Racke, et al.
Neurobiology of Disease|May 8, 2012
K+ channel alterations in the progression of experimental autoimmune encephalomyelitisPeter I Jukkola, Amy E Lovett-Racke, Scott S Zamvil, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|July 8, 2015
CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and DiseaseKathryn J Jones, Amy E Lovett-Racke, Chandler L Walker, et al.
Journal of Neuroimmunology|October 9, 2007
Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosisRodney Stuart, Amy E Lovett-Racke, Elliot M Frohman, et al.
Frontiers in Immunology|June 20, 2018
IL-3 Is a Marker of Encephalitogenic T Cells, but Not Essential for CNS AutoimmunityPriscilla W Lee, Matthew K Xin, Wei Pei, et al.
Experimental Neurology|October 4, 2011
The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured miceAkshata Almad, A Todd Lash, Ping Wei, et al.
Journal of Neuroimmunology|December 20, 2005
Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunityBaranda S Hansen, Rehana Z Hussain, Amy E Lovett-Racke, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Frontiers in Molecular Neuroscience|November 11, 2017
Suppression of Inflammatory Demyelinaton and Axon Degeneration through Inhibiting Kv3 ChannelsPeter Jukkola, Yuanzheng Gu, Amy E Lovett-Racke, et al.
Expert Review of Clinical Immunology|May 19, 2010
Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosisMark T Muir, Amy E Lovett-Racke, Michael K Racke
Frontiers in Neurology|June 2, 2022
Vitamin D as a Risk Factor for Multiple Sclerosis: Immunoregulatory or Neuroprotective?Sara E Gombash, Priscilla W Lee, Elizabeth Sawdai, et al.
Brain, Behavior, and Immunity|December 16, 2014
Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosisPriscilla W Lee, Yuhong Yang, Michael K Racke, et al.
Neurobiology of Disease|May 8, 2012
K+ channel alterations in the progression of experimental autoimmune encephalomyelitisPeter I Jukkola, Amy E Lovett-Racke, Scott S Zamvil, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|July 8, 2015
CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and DiseaseKathryn J Jones, Amy E Lovett-Racke, Chandler L Walker, et al.
Journal of Neuroimmunology|October 9, 2007
Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosisRodney Stuart, Amy E Lovett-Racke, Elliot M Frohman, et al.
Frontiers in Immunology|June 20, 2018
IL-3 Is a Marker of Encephalitogenic T Cells, but Not Essential for CNS AutoimmunityPriscilla W Lee, Matthew K Xin, Wei Pei, et al.
Experimental Neurology|October 4, 2011
The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured miceAkshata Almad, A Todd Lash, Ping Wei, et al.
Journal of Neuroimmunology|December 20, 2005
Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunityBaranda S Hansen, Rehana Z Hussain, Amy E Lovett-Racke, et al.
Pageof 7